News & Updates
Showing Ophthalmology articles
Showing
Which factor predicts successful interval extension in eyes with nAMD switched to brolucizumab?
In patients with neovascular age-related macular degeneration (nAMD) who switched to brolucizumab treatment, those with shorter treatment interval before switching are more likely to have successful injection interval extension, as shown in a study.
Amblyopia protective against age-related macular degeneration
Less amblyopic individuals are more likely to have age-related macular degeneration (AMD) diagnosed on the amblyopic eye than on the nonamblyopic eye, as reported in a study. Meanwhile, individuals with lateral asymmetry tend to have the more advanced form of AMD on the nonamblyopic eye.
Patient-reported tool helps assess symptoms, vision perception after IOL implantation
Use of the 37-item Assessment of IntraOcular Lens Implant Symptoms (AIOLIS) instrument appears effective in evaluating symptoms and general perceptions of vision associated with cataract surgery and intraocular lens (IOL) implants, reports a study.
OPT-302 2.0 mg plus ranibizumab leads to superior vision gains in nAMD
Treatment with 2.0-mg OPT-302, a biologic inhibitor of vascular endothelial growth factor (VEGF)-C and D, in combination with ranibizumab, an anti‒VEGF-A inhibitor, results in greater vision gains when compared with the current standard of care for neovascular age-related macular degeneration (nAMD), reports a study. In addition, the combined therapy has an acceptable safety profile.
Dietary modification ups glaucoma risk in women
Dietary modification (DM) among individuals in the lowest quartile for percentage calories from total fat at baseline is associated with a higher risk of incident primary open-angle glaucoma (POAG) among women, irrespective of age or race, suggests a recent study.